Expression of PPARγ and Its Ligand-dependent Growth Inhibition in Human Brain Tumor Cell Lines
✍ Scribed by Kato, Mihoko ;Nagaya, Takashi ;Fujieda, Miyuki ;Saito, Kiyoshi ;Yoshida, Jun ;Seo, Hisao
- Book ID
- 108582147
- Publisher
- Wiley (Blackwell Publishing)
- Year
- 2002
- Tongue
- English
- Weight
- 603 KB
- Volume
- 93
- Category
- Article
- ISSN
- 0910-5050
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The glycoprotein A33 (GPA33) is a colon cancer antigen. Phase I trials with ^131^I and ^125^I monoclonal antibody A33 in colon carcinoma patients showed excellent localization to colorectal cancer and some evidence of tumor response. Using DNA microarrays, we have identified the __GPA33
Basic fibroblast growth factor (bFGF) has been shown to be mitogenic to many different eukaryotic cell lines of mesodermal and neuroectoderrnal origin. Addition of exogenous bFCF to the chemically defined media of five characterized human colon tumor cell lines, cultured in the absence of epidermal
Compound 48 (C48) is a novel dual ligand for peroxisome proliferator-activated receptor alpha and gamma (PPAR alpha/gamma). Culture of imatinib-sensitive and -resistant CML cell lines with C48 resulted in a strong growth inhibition which associated with G0/G1 cell cycle arrest. However, it showed no